Why the study?
Limited prospective studies have examined the impact of the CBR3 V244M single nucleotide polymorphism on the risk for anthracycline-related cardiotoxicity in adult cohorts.
Does the CBR3 V244M genotype affect the risk of LVEF reduction in breast cancer patients treated with doxorubicin?
Does the CBR3 V244M genotype affect the risk of LVEF reduction in breast cancer patients treated with doxorubicin?
The CBR3 V244M genotype is associated with early anthracycline-related cardiomyopathy, with the GG genotype showing a greater reduction in LVEF compared to the AG genotype in breast cancer patients treated with doxorubicin.
No takes yet. Share an insight, caveat, or question.
CBR3 GG genotype was associated with greater early LVEF decline after doxorubicin; leaves open whether genotyping should guide anthracycline use in breast cancer.
Lang et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: